RxDoctor Payments Data

James Hall, MD

Internal Medicine · Pampa, TXNPI 1073533956

Payments from drug & device makers

$1,812in general payments, 2019–2025

Across 109 payments — averaging $16.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mylan Specialty L.p.$440
  • Pfizer$201
  • Novo Nordisk$177
  • Astellas Pharma US Inc$122
  • Lilly USA, LLC$99
  • Amgen$87
  • plus $686 from 17 others

What the payments were for

  • Food & beverage$1,71395%
  • Education$995%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,812 in reported general payments places this provider in the 75th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$432,898
Medicare patients
673
Services billed
4,875

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide44$41,870
Trelegy ElliptaFluticasone/Umeclidin/Vilanter46$30,548
EliquisApixaban45$25,005
MounjaroTirzepatide18$18,003
XareltoRivaroxaban25$16,914
RybelsusSemaglutide13$14,126
LinzessLinaclotide17$11,533
JanuviaSitagliptin Phosphate13$8,645
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen150$5,263
Lantus SolostarInsulin Glargine,hum.Rec.Anlog27$4,276
Gabapentin146$3,180
Ivermectin12$3,075
Atorvastatin Calcium215$2,388
Albuterol Sulfate HfaAlbuterol Sulfate74$1,878
Dexlansoprazole DrDexlansoprazole11$1,762

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$177$55,99657 claims
GSKTrelegy Ellipta$73$30,54846 claims
PfizerEliquis$201$25,00545 claims
Lilly USA, LLCMounjaro$99$18,00318 claims
Johnson & JohnsonXarelto$21$16,91425 claims
AbbVieLinzess$42$11,53317 claims
MerckJanuvia$74$8,64513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Pampa

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →